text
stringlengths 0
197k
|
|---|
<|newrecord|> nctId: NCT06355713 id: 69HCL23_0899 id: 2023-A02010-45 type: OTHER domain: ID-RCB briefTitle: Improvement of Symptoms After Removal of the Essure® Contraceptive Implant acronym: ABLES overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2031-08-01 date: 2036-06-01 date: 2024-04-09 date: 2024-04-09 name: Hospices Civils de Lyon class: OTHER briefSummary: ESSURE® is an implantable medical device for definitive and irreversible sterilization indicated for adult women of childbearing age. These implants are inserted into the fallopian tubes by hysteroscopy. Marketed in 2002, ESSURE® contraceptive implants were withdrawn from the French market in 2017 (and worldwide in 2017 and 2018) following the observation in certain patients of polymorphic and non-specific gynecological and extra-gynecological symptoms. Studies with small numbers and short-term follow-up have shown a significant improvement in these symptoms after implant explantation. This constitutes a real public health problem since according to the report of the EPI-PHARE Scientific Interest Group, 198,000 French women have these implants and only 30,000 of them, or 15%, have been explanted, knowing that explantation of ESSURE® implants is recommended only in symptomatic patients. A large number of these patients, presenting symptoms, have not yet been treated for an explant.
|
The physiopathological mechanism(s) is (are) not yet determined but several arguments are in favor of a dissemination of metallic elements contained in these implants whose accumulation could lead to inflammatory and/or allergic and/or autoimmune phenomena.
|
Carrying out a prospective study with long-term longitudinal follow-up appears essential to precisely assess the degree of improvement in the symptoms and quality of life of these patients, determine the most appropriate surgical techniques, and understand the pathophysiological mechanisms that may result in the implementation of specific treatments and relevant markers. From a surgical point of view, there is a real risk of fracture of implants whatever the type of intervention performed: study the biomechanical properties of implants with a view to characterizing their behavior to mechanical rupture but also their thermal resistance in an objective manner seems essential to limit the risk of fracture and help to inform the patient about the surgical technique proposed for explantation. From a biological point of view, the dosage of the metallic elements constituting ESSURE® implants and potentially toxic ones could make it possible to objectify the release of these metallic elements in the body. Analysis of pro-inflammatory cytokines, micro-RNAs (miRNA), quantitative analysis of inflammatory pathway messenger ribonucleic acid (mRNAs) (NanoString technology) and analysis of neuroinflammation by functional imaging should make it possible to explore potential pathophysiological mechanisms. This study responds to a significant request from patient associations. conditions: Implant Complication conditions: Contraceptive Device; Complications studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 444 type: ESTIMATED name: Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination name: blood sample name: urine collection name: Collection of a lock of hair name: questionnaire measure: Percentage of patients with improvement in symptoms Percentage of patients with improvement in symptoms measure: Percentage of patients with improvement in symptoms measure: Short Form 12 (SF-12) score measure: Fibromyalgia Impact Questionnaire (FIQ) score measure: Hospital Anxiety and Depression scale (HADS) score measure: Multidimensional Fatigue Inventory (MFI)-20 score measure: Visual analog scale (VAS) score measure: Questionnaire Douleur St-Antoine (QDSA) score measure: Female Sexual Function Index (FSFI) score measure: Higham questionnaires measure: visual analog scale (VAS) score measure: Duration of the procedure measure: Complications measure: characterization of the mechanical behavior of the implant measure: determination of the associated mechanical stress levels determination of the associated mechanical stress levels measure: quantification of the factors influencing these levels of mechanical stress measure: thermal resistance measure: risk of degradation measure: Concentrations of titanium constituting the Essure® implant measure: Concentrations of nickel constituting the Essure® implant measure: Concentrations of chromium constituting the Essure® implant measure: Concentrations of tin constituting the Essure® implant measure: Concentrations of platinum constituting the Essure® implant measure: Concentrations of iridium constituting the Essure® implant measure: Concentrations of molybdenum constituting the Essure® implant measure: Concentrations of manganese constituting the Essure® implant measure: Concentrations of tungsten constituting the Essure® implant measure: Concentrations of silver constituting the Essure® implant measure: Concentrations of iron constituting the Essure® implant measure: concentration of pro-inflammatory cytokines measure: expression profile of miRNAs measure: activated T lymphocyte profile measure: analysis of inflammatory pathway mRNAs measure: Percentage of detection of Human Leukocyte Antigen measure: Functional brain functions sex: FEMALE minimumAge: 35 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Angers city: Angers zip: 49933 country: France name: Guillaume Legendre, PU,PH role: CONTACT phone: 0241354635 phoneExt: +33 email: [email protected] name: Guillaume Legendre, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 47.46667 lon: -0.55 facility: Hôpital Femme Mère Enfant (Hospices Civils de Lyon) city: Bron zip: 69677 country: France name: Gautier Chene, PU,PH role: CONTACT phone: 0472355870 phoneExt: +33 email: [email protected] name: Gautier Chene, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 45.73333 lon: 4.91667 facility: Hôpital Bicêtre city: Le Kremlin-Bicêtre zip: 94275 country: France name: Perrine CAPMAS, PU,PH role: CONTACT phone: 0145217714 phoneExt: +33 email: [email protected] name: Perrine CAPMAS, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.81471 lon: 2.36073 facility: Hôpital Jeanne de Flandres city: Lille zip: 59037 country: France name: Victoire Delporte, PU,PH role: CONTACT phone: 0320446641 phoneExt: +33 email: [email protected] name: Victoire Delporte, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 50.63297 lon: 3.05858 facility: Hôpital de La Conception city: Marseille zip: 13005 country: France name: Aubert Agostini, PU,PH role: CONTACT phone: 0491383702 phoneExt: +33 email: [email protected] name: Aubert Agostini, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 43.29551 lon: 5.38958 facility: Institut Mère Enfant Alix de Champagne, CHU Reims city: Reims zip: 51092 country: France name: Olivier Graesslin, PU,PH role: CONTACT phone: 0326783517 phoneExt: +33 email: [email protected] name: Olivier Graesslin, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 49.25 lon: 4.03333 facility: CHU de Rouen city: Rouen zip: 76000 country: France name: Patrice Crochet, PU,PH role: CONTACT phone: 0232881054 phoneExt: +33 email: [email protected] name: Patrice Crochet, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 49.44313 lon: 1.09932 facility: Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg city: Strasbourg zip: 67200 country: France name: Thomas Boisrame, PU,PH role: CONTACT phone: 0388127458 phoneExt: +33 email: [email protected] name: Thomas Boisrame, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.58392 lon: 7.74553 facility: Hôpital Paule de Viguier, CHU de Toulouse city: Toulouse zip: 31059 country: France name: Yann Tanguy Le Gac, PU,PH role: CONTACT phone: 0567771105 phoneExt: +33 email: [email protected] name: Yann Tanguy Le Gac, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 43.60426 lon: 1.44367 facility: Hôpital André Mignot, Centre Hospitalier de Versailles city: Versailles zip: 78157 country: France name: Pierre Panel, PU,PH role: CONTACT phone: 0139638936 phoneExt: +33 email: [email protected] name: Pierre Panel, PU,PH role: PRINCIPAL_INVESTIGATOR lat: 48.8 lon: 2.13333 hasResults: False
|
<|newrecord|> nctId: NCT06355700 id: 5476 briefTitle: Hepatocellular Carcinoma Liver Organoids acronym: HELIO overallStatus: RECRUITING date: 2023-06-15 date: 2025-03 date: 2025-03 date: 2024-04-09 date: 2024-04-09 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The goal of this interventional study is to create hepatocellular carcinoma organoids from liver bioptic samples of individuals with hepatocellular carcinoma. The main questions it aims to answer are:
|
* the feasibility of hepatocellular carcinoma organoids integrated with host gut microbiota and peripheral blood mononuclear cells
|
* the molecular pattern of the organoid tumor microenvironment
|
* the in vitro therapeutic response of hepatocellular carcinoma organoids conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: Liver biopsy measure: Success rate of hepatocellular carcinoma organoids integrated with host gut microbiota and peripheral blood mononuclear cells measure: Analysis of hepatocellular carcinoma organoid transcriptome distribution within a reference set from The Cancer Genome Atlas measure: Evaluation of the concordance of somatic genetic mutations between the organoid and the original tumor measure: Correlation between gut microbiota community profiling and growth rate of hepatocellular carcinoma organoids measure: Treatment response evaluation in vitro sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Agostino Gemelli IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: Francesca Ponziani, MD role: CONTACT phone: +390630156018 email: [email protected] lat: 41.89193 lon: 12.51133 hasResults: False
|
<|newrecord|> nctId: NCT06355687 id: FMASU MD304/2023 briefTitle: Melatonin in Obese Patients in Laparoscopic Cholecystectomy overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-09 date: 2024-04-09 name: Ain Shams University class: OTHER briefSummary: Opioid free anesthesia (OFA) means a technique in which no intraoperative opioid is administered through any route. Perioperative pain management in an obese patient is challenging. The incidence of respiratory depression is higher in obese patients and is exaggerated with opioids, so the investigators are searching for a drug that has analgesic effect without any effect on respiratory function. In this study, the investigators will add melatonin to OFA in obese patients undergoing laparoscopic cholecystectomy. conditions: Anesthesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Melatonin name: Vitamin Supplement measure: Postoperative Pain. measure: Postoperative Pain. measure: Analgesics usage. measure: Postoperative nausea and vomiting. measure: Recovery time. measure: Number of participants with hemodynamic instability. measure: Number of participants with hemodynamic instability. sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355674 id: HRÜ/23.21.12 briefTitle: Adolescent Mother and Breastfeeding Education overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-09-15 date: 2024-10-15 date: 2024-04-09 date: 2024-04-09 name: Adiyaman University class: OTHER briefSummary: In low-income and developing countries, 30% of adolescents marry before the age of 18, and 14% marry before the age of 15. Additionally, adolescents between the ages of 15 and 19 are often coerced into marriage or sexual relationships with partners older than themselves. 10% of adolescents under the age of 15 in the world are forced to have sexual intercourse and as a result, unwanted teenage pregnancies occur. In high-income countries like Latin America, there is a high prevalence of adolescent non-marital pregnancies. When considering the fertility, health, and social outcomes of adolescence, it emerges as a significant issue. Adolescent motherhood carries numerous adverse effects from both demographic and social perspectives.
|
In pregnancies occurring during adolescence, both maternal and infant mortality rates are two to three times higher compared to pregnancies at later ages. Many infant and child deaths occur due to preventable causes. Breastfeeding is a significant factor in reducing infant and child mortality. Since infants born to adolescent mothers are at higher risk of death and illness, breastfeeding these infants becomes even more important. However, one of the significant challenges adolescent mothers face during the postpartum period is initiating and maintaining lactation. Research has shown that maternal age plays a significant role in initiating and sustaining breastfeeding, with a strong positive correlation between maternal age and duration of breastfeeding. This study was designed as a randomized controlled trial to examine the effect of breastfeeding education provided to adolescent mothers on maternal breastfeeding self-efficacy, mother-infant attachment, and infant anthropometric measurements. conditions: Adolescent Mother studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 80 type: ESTIMATED name: Breastfeeding education provided with Lactation Simulation Model measure: Postnatal Breastfeeding Self-Efficacy Scale-Short Form measure: Maternal-Infant Attachment Scale sex: FEMALE minimumAge: 12 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355661 id: HP/231102/PA/URTI briefTitle: A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-05-15 date: 2024-06-01 date: 2024-04-09 date: 2024-04-09 name: Vedic Lifesciences Pvt. Ltd. class: INDUSTRY briefSummary: The present study is a randomized, double-blind, placebo-controlled, comparative study. 176 individuals will be screened, and considering a screening failure rate of 15 percent approximately 150 will be randomized in a ratio of 1:1 to receive either IP or placebo and will be assigned a unique randomization code. Each group will have at least 60 completed participants after accounting for a dropout/withdrawal rate of 20percent. The intervention duration for all the study participants is 7 days conditions: Upper Respiratory Tract Infections studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A Double-blind, Randomized, Placebo-Controlled primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule name: MCC: 400 mg (± 10%) per Capsule measure: To evaluate the effect of investigational products on participant's severity of common cold like symptoms measure: To evaluate the effect of investigational products on Time (in days) taken to resolution of common cold like symptoms measure: To evaluate the effect of investigational products on Percentage of participants with unresolved common cold symptoms measure: To evaluate the effect of investigational products on Percentage of population with minimal important difference of ≥ 10.3 as per change in Wisconsin Upper Respiratory Symptom Survey-21 total score. (daily score will be analysed in study) measure: To evaluate the effect of investigational products on Number of days taken to be afebrile (temp < 100 oF/< 37.7 ºC) in the population with fever (temp ≥100oF or ≥37.7 ºC ) at baseline- as assessed by 10-point visual analogue scale. measure: To evaluate the effect of investigational products on Percentage population with fever during the study. measure: To evaluate the effect of investigational products on Quality of life as assessed by Wisconsin Upper Respiratory Symptom Survey Quality of Life sex: ALL minimumAge: 16 Years maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Biswas health care & Diagnostic Centre city: Nainital state: Uttaranchal country: India name: Dr Bijay Biswas, MBBS,MD role: CONTACT phone: 919760010003 email: [email protected] lat: 29.39743 lon: 79.44686 hasResults: False
|
<|newrecord|> nctId: NCT06355648 id: IRAS 337181 briefTitle: Advanced Clinical Practitioners in the ED overallStatus: NOT_YET_RECRUITING date: 2024-05-03 date: 2024-10-01 date: 2025-03-01 date: 2024-04-09 date: 2024-04-09 name: King's College London class: OTHER briefSummary: No patient data is involved in the study. This study is designed to understand better how Emergency Care Advanced Clinical Practitioners (EC-ACPs) work in emergency departments (EDs). The main research question is:
|
1) What is the EC-ACP's perception of assimilation into emergency care teams, what tensions are created due to the role, and what system adaptations are required to facilitate integration?
|
With secondary aims :
|
1. What are the common organisational factors that affect the implementation of the EC-ACP workforce, and what recommendations can be made to improve Trust-wide implementation?
|
2. How are EC-ACPs deployed in two contrasting emergency departments, what differences can be identified in their Work-As-Done (WAD), and how does this compare to the Work-As-Imagined (WAI) of the role?
|
Participants will all be staff members who work in the hospital. Patient data is not being collected or processed. This is a mixed-method study using two approaches to collect data:
|
1. Observation of the EC-ACPs at work - noting how they interact with colleagues and how they are deployed in the ED.
|
2. Interviews with various staff who work with the EC-ACPs clinically or in various managerial or director roles.
|
Background
|
In the UK, a health care role has been developed called Advanced Clinical Practitioners (ACPs). ACPs work in various clinical settings, but this study focuses on those in Emergency Care. While non-medical practitioners have worked in Emergency Departments (EDs) for over 20 years, the ACP role is relatively new. Most ACPs in ED are from a nursing or paramedical background, but they can also be from other allied health professions like physiotherapy. After the base qualification, ACPs undertake a three-year master\'s degree with clinical portfolios. Once qualified, the goal is to create clinicians who work alongside doctors, seeing, treating, and discharging patients. Unlike previous practitioner roles, EC-ACPs treat the whole spectrum of ED patients, from minor injuries and illnesses to the sickest patients needing the highest level of care.
|
These roles were heavily supported by local and political desires to create blended workforces to meet increasing patient demands. The problem with implementing ACP roles is that initially, little consultation was held with stakeholders in EDs. This has resulted in various trade-offs. For example, trainee doctors often feel displaced by trainee ACPs seeking to learn the same or similar skills.
|
Previous research on advanced roles in ED has focused on direct clinical comparisons between doctors and practitioners. Researchers have investigated which professional (doctors vs. nurse practitioners) triages patients quickest or who is more accurate at interpreting X-rays. There are several problems with these approaches. The first is that they can create a professional rivalry. The second problem is that these approaches oversimplify what is a more complex system of care. conditions: Healthy Volunteers studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: Narrative data measure: Narrative data sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355635 id: JohannesGUVA briefTitle: Application and Monitoring of Vasoactive and Inotrope Drugs acronym: Vasin overallStatus: RECRUITING date: 2024-04-04 date: 2024-06-01 date: 2024-11-01 date: 2024-04-09 date: 2024-04-09 name: Johannes Gutenberg University Mainz class: OTHER briefSummary: The investigators aimed to establish current practice of application and monitoring of vasoactive and inotrope Drugs in non-cardiac surgery patients. conditions: Hemodynamic Instability studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Choice and Monitoring measure: current practice of correct application and monitoring of vasoactive and inotrope Drugs sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Anaesthesiology; status: RECRUITING city: Mainz state: Rhineland-Palatinate zip: D55131 country: Germany name: Marc Kriege, MD role: CONTACT phone: 00496131170 email: [email protected] lat: 49.98419 lon: 8.2791 hasResults: False
|
<|newrecord|> nctId: NCT06355622 id: 3717 briefTitle: Prevalence and Characterization of Pain in RASopathies acronym: 3717 overallStatus: RECRUITING date: 2021-01-27 date: 2024-01-30 date: 2024-06-30 date: 2024-04-09 date: 2024-04-09 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: RASopathies are a group of syndromes caused by variants in genes belonging to the RAS/MAPK pathway. Pain is a neglected topic in RASopathies but it is frequently complained by affected individuals. conditions: RASopathy conditions: Costello Syndrome conditions: Cardio-Facio-Cutaneous Syndrome conditions: Noonan Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 150 type: ESTIMATED name: Characterization of pain measure: Prevalence of pain in verbal patients with RASopathies measure: Prevalence of Pain in no-communitating patients with RASopathies measure: Characterization of pain in RASopathies sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Woman and Child Health and Public Health, Fondazione Policlinico A. Gemelli, IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: Chiara Leoni, MD, PhD role: CONTACT phone: 0039063381344 email: [email protected] lat: 41.89193 lon: 12.51133 hasResults: False
|
<|newrecord|> nctId: NCT06355609 id: DZ2023EI004-RW briefTitle: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW acronym: WUKONG-32-RW overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-12-30 date: 2027-12-30 date: 2024-04-09 date: 2024-04-09 name: Hunan Province Tumor Hospital class: OTHER briefSummary: This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive non-small cell lung cancer. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: sunvozertinib in combination with Anlotinib measure: Progression-free survival (PFS) measure: Objective Response Rate (ORR) measure: Overall survival (OS) measure: Duration of Response (DoR) measure: Adverse events (AEs) according to CTCAE 5.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hunan Cancer Hospital city: Changsha state: Hunan zip: 410013 country: China lat: 28.19874 lon: 112.97087 hasResults: False
|
<|newrecord|> nctId: NCT06355596 id: 20IC6361 briefTitle: Development and Validation of a Virtual Teaching Method for Minimally Invasive Surgery Skills overallStatus: COMPLETED date: 2022-03-11 date: 2022-04-08 date: 2022-04-08 date: 2024-04-09 date: 2024-04-09 name: Imperial College London class: OTHER briefSummary: The goal of this observational study is to develop and evaluate a virtual teaching method for minimally invasive surgery (MIS) skills among novice learners, using widely available technology and incorporating objective assessments of proficiency. The main questions it aims to answer are:
|
Can MIS skills be effectively taught to novice learners through a virtual platform using widely available technology? How do virtual and face-to-face (F2F) teaching methods compare in terms of effectiveness, measured by performance in MIS tasks and cognitive workload parameters?
|
Participants in this study will:
|
Be randomly allocated to either F2F or virtual teaching groups. Undergo training and evaluation using validated laparoscopic assessments, namely the McGill Inanimate System for Training and Evaluation of Laparoscopic Skills (MISTELS) peg transfer task and the European Academy laparoscopic 'Suturing Training and Testing' (SUTT) assessment.
|
Have their performance and cognitive workload parameters (SURG-TLX score, heart rate, and pupil metrics) evaluated during the tasks. conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Participants are randomly allocated to either face-to-face or virtual teaching groups primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ACTUAL name: Virtual teaching measure: McGill Inanimate System for Training and Evaluation of Laparoscopic Skills (MISTELS) peg transfer task score measure: European Academy laparoscopic 'Suturing Training and Testing' (SUTT) assessment score measure: SURG-TLX score measure: Heart rate measure: Pupil metrics sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: St Mary's Hospital city: London zip: W2 1NY country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
|
<|newrecord|> nctId: NCT06355583 id: C/42/2022 id: 2022-003617-10 type: EUDRACT_NUMBER briefTitle: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial acronym: MAST overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-02-01 date: 2027-05-01 date: 2024-04-09 date: 2024-04-09 name: Imperial College London class: OTHER briefSummary: The goal of this clinical trial is to test the ability to restore gut microbiota to healthier levels in patients with blood cancers scheduled to have stem cell transplant.
|
The main questions it aims to answer are:
|
* Tolerability and acceptability of intestinal microbiota transplantation (IMT) versus placebo (as assessed via patient perspective questionnaires
|
* Changes in gut microbiome diversity across all timepoints
|
* Markers of general health, infective/microbiological and haematological outcomes including, days of fever, admission to intensive care unit, survival, non-relapsed mortality, and incidence of graft-versus-host disease across all time points measured.
|
Participants will be asked at their routine follow up visits to,
|
* Provide stool, urine and blood samples at the scheduled study visits
|
* Complete questionnaires at selected visits
|
* Swallow either Placebo or IMT capsules once at the second study visit which will occur 2 weeks prior to the stem cell transplant (+/-3 days)
|
Researchers will compare IMT capsules and Placebo to investigate the change in gut microbiota diversity. conditions: Acute Lymphoblastic Leukaemia conditions: Acute Leukemia of Ambiguous Lineage conditions: Chronic Myeloid Leukemia conditions: Chronic Myelomonocytic Leukemia conditions: Myelodysplastic Syndrome conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: EBX-102 name: Placebo measure: Change in gut microbiota diversity using Inverse Simpsons Index measure: Gut Microbiome Diversity - Alpha diversity measure: Alpha Diversity - Chao1 Index measure: Alpha Diversity - Shannon Index measure: Alpha Diversity - Faiths Phylogenetic Diversity (Faiths PD) measure: Beta Diversity - Aitchison Distance measure: Gut Microbiome Taxonomic Composition measure: Markers of general health - ITU Admission measure: Quality of life EQ-5D-5L measure: Quality of Life EORTC-QLQ-C30 measure: Infective Haematological Outcomes - Fever Occurrence measure: Infective Haematological Outcomes - Fever CTCAE Grade measure: Infective Haematological Outcomes - Infection measure: Infective Haematological Outcomes - Multi drug Resistant Bacterial Colonisation (MDROs) measure: Infective Haematological Outcomes - Antibiotic Use measure: Markers of General Health - Severity of Mucositis measure: Markers of General Health -Occurrence of Severe Acute Kidney Injury (AKI) measure: Markers of General Health - Occurrence of Severe liver dysfunction measure: Markers of general health - Use of Parenteral Nutrition measure: Neutrophil and platelet engraftment data measure: Recovery of T-cell Chimaerisms, measure: Haematological Outcomes - Non-relapsed mortality measure: Haematological Outcomes - Occurrence Graft vs Host Disease measure: Haematological Outcomes - Severity of graft vs Host Disease measure: Overall Survival measure: Graft-versus disease-free relapse-free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Birmingham NHS Foundation Trust city: Birmingham state: England zip: B15 2WB country: United Kingdom name: Senior Haematology Research Sister role: CONTACT phone: 01213714351 email: [email protected] name: Francesca Kinsella role: PRINCIPAL_INVESTIGATOR lat: 52.48142 lon: -1.89983 facility: Leeds Teaching Hospital NHS Trust city: Leeds state: England zip: LS9 7TF country: United Kingdom name: Principal Investigator role: CONTACT phone: 01132068561 email: [email protected] lat: 53.79648 lon: -1.54785 facility: University College London Hospitals NHS Trust city: London state: England zip: NW1 2BU country: United Kingdom name: BMT Trials role: CONTACT email: [email protected] name: Panagiotis Kottaridis role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Kings College NHS Foundation Trust city: London state: England zip: SE5 9RS country: United Kingdom name: Principal Investigator role: CONTACT email: [email protected] name: Pramila Krishnamurthy role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 facility: Imperial College Healthcare NHS Trust city: London state: England zip: W12 0NN country: United Kingdom name: Senior Research Operations Manager role: CONTACT phone: 02037048452 email: [email protected] lat: 51.50853 lon: -0.12574 facility: Royal Mardsen Hostpital city: London zip: SW3 6JJ country: United Kingdom name: Haemato-Oncology Department role: CONTACT phone: 0208915 6187 email: [email protected] name: Emma Nicholson role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
|
<|newrecord|> nctId: NCT06355570 id: 331314 id: RFPR2324_29 type: OTHER_GRANT domain: Imperial Health Charity id: 24/YH/0011 type: OTHER domain: UK Health Research Authority (Research Ethics Committee) briefTitle: Delirium After Cardiac Surgery in Intensive Care Units acronym: DaCsi-ICU overallStatus: RECRUITING date: 2024-03-20 date: 2024-12-31 date: 2025-03-20 date: 2024-04-09 date: 2024-04-11 name: Imperial College Healthcare NHS Trust class: OTHER briefSummary: STUDY SUMMARY
|
STUDY DESIGN The study will be conducted over twelve months in the Cardiac Intensive Care Unit (ICU) at Hammersmith Hospital, Imperial College Healthcare NHS Trust (ICHT). This study is a mixed methods research design that includes the collection of data through qualitative interviews, quality-of-life questionnaires and patients' medical records.
|
AIMS
|
* Determine the incidence of ICU delirium in ICHT following cardiac surgery
|
* Explore the compliance of outcome measures that diagnose ICU delirium
|
* Implement a family-focused sensory stimulation programme in the ICU
|
* Evaluate its useability and potential impact on patients, families and ICU staff
|
STUDY POPULATION 30 study participants (12 patients, 12 family members/friends and 6 ICU nurses)
|
ELIGIBILITY Study eligibility criteria are specific for each care group (patients, family members/friends and ICU nurses).
|
DURATION 12 months at Hammersmith Hospital, ICHT conditions: Intensive Care Unit Delirium conditions: Cardiac Surgery conditions: Post Operative Delirium studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: 12-patient participants will be submitted to the study intervention. primaryPurpose: BASIC_SCIENCE masking: NONE count: 30 type: ESTIMATED name: Personal Pictures name: Family Videos name: Family Videos - Intervention as required measure: Feasibility of implementing the study intervention measure: Practicalities of introducing the study intervention measure: Acceptability of implementing the study intervention measure: Short-term delirium outcomes post-ICU discharge sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Imperial College Healthcare NHS Trust status: RECRUITING city: London zip: W12 0HS country: United Kingdom name: Maria Reguenga, BSN role: CONTACT phone: +442033131703 email: [email protected] name: Sanooj Soni, PhD role: CONTACT phone: 07714329708 email: [email protected] lat: 51.50853 lon: -0.12574 hasResults: False
|
<|newrecord|> nctId: NCT06355557 id: DSRB 2023/00640 briefTitle: Human vs Machine: a RCT Comparing Traditional In-person Instruction, AI Versus VR for Learning Basic CCE overallStatus: RECRUITING date: 2024-04-04 date: 2024-12-31 date: 2025-01 date: 2024-04-09 date: 2024-04-09 name: Tan Tock Seng Hospital class: OTHER briefSummary: The aim of the study is to investigate if hands-on training for basic CCE with virtual reality simulators or guided by artificial intelligence is non-inferior to training by an experienced instructor. conditions: Ultrasound studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 3-arm prospective randomised controlled trial. primaryPurpose: OTHER masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: AI enabled ultrasound system for self-directed learning name: Simulator for self-directed learning name: traditional with human instructors measure: Improvement in image acquisition and structure identification at the end of 3 months. sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tan Tock Seng Hospital status: RECRUITING city: Singapore zip: 319581 country: Singapore name: Yie H Lau role: CONTACT phone: 6563577771 email: [email protected] name: Yie H Lau role: PRINCIPAL_INVESTIGATOR lat: 1.28967 lon: 103.85007 hasResults: False
|
<|newrecord|> nctId: NCT06355544 id: PINEAPPL2023 id: 2023-A02494-41 type: OTHER domain: Agence nationale de sécurité du médicament et des produits de santé briefTitle: Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk acronym: PINEAPPL overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-05-30 date: 2026-06-30 date: 2024-04-09 date: 2024-04-09 name: Integrative Phenomics class: INDUSTRY name: Assistance Publique - Hôpitaux de Paris name: Assistance Publique Hopitaux De Marseille name: University Hospital, Bordeaux name: Centre Hospitalier Universitaire Dijon name: Institut Pasteur de Lille name: Hopitaux Civils de Colmar briefSummary: The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity.
|
The main questions it aims to answer are:
|
* Whether it is possible to predict low-grade inflammation
|
* What are the medical, biological, and lifestyle variables related to low-grade inflammation?
|
Participants will be asked to:
|
1. Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples.
|
2. Complete questionnaires and collect a stool sample at home. conditions: Overweight conditions: Obesity conditions: Metabolic Syndrome conditions: Healthy conditions: Low-grade Inflammation conditions: Normal Weight Adults conditions: Risk Factor, Cardiovascular conditions: Hypertension conditions: Hypercholesterolemia conditions: Abdominal Obesity conditions: Metabolically Healthy Controls studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 3000 type: ESTIMATED measure: Low-grade inflammation measure: Gut microbiome metabolites measure: Fasting glucose measure: Stool microbiome composition measure: Stool microbiome functional pathways measure: Systolic blood pressure measure: Resting heart rate measure: Serum glycated hemoglobin (HbA1c) measure: Diastolic blood pressure measure: Height measure: Waist circumference measure: Neck circumference measure: Hip circumference measure: Body fat mass measure: Water body mass measure: Lean body mass measure: Serum fasting low-density lipoprotein measure: Fasting serum high-density lipoprotein measure: Fasting total serum cholesterol measure: Consumption of dietary macronutrients measure: Consumption of dietary micronutrients measure: Consumption of dietary metabolites measure: Food item consumption measure: Food group consumption measure: Body weight measure: Serum Alanine Transaminase (ALT) measure: Serum Aspartate Aminotransferase (ALT) measure: Serum gamma-glutamyl transferase (GGT) measure: Fasting serum triglycerides measure: Fasting serum uric acid measure: Fasting serum creatinine measure: Fasting serum insulin measure: Blood hemoglobin measure: Blood hematocrit measure: Red blood cells measure: Red blood cell volume measure: Hemoglobin relative red blood cell size measure: Mean cell hemoglobin (MCH) measure: Blood platelets measure: White blood cells measure: Perceived quality of life measure: Eating behavior measure: Physical activity measure: Stool consistency measure: Stress measure: Deprivation measure: Sleep measure: Sleep apnea sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355531 id: FNP223-CT-2301 briefTitle: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-11 date: 2026-11 date: 2024-04-09 date: 2024-04-09 name: Ferrer Internacional S.A. class: INDUSTRY briefSummary: PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP. conditions: Progressive Supranuclear Palsy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 220 type: ESTIMATED name: FNP-223 name: Placebo measure: Change From Baseline to Week 52 in the PSPRS Outcome measure: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) measure: Number of Participants Experiencing Serious Adverse Events (SAEs) measure: Change From Baseline to Week 52 in Clinical Global Impression of Severity Scale (CGI-S) measure: Change From Baseline to Week 52 Participant Global Impression of Severity Scale (PGI-S) measure: Change From Baseline to Week 52 in Caregiver Global Impression of Severity Scale (CaGI-S) measure: Slope of Decline in PSPRS measure: Change From Baseline to Week 52 in Individual Subitems of PSPRS measure: Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale measure: Change From Baseline to Week 52 in PSP Clinical Deficits Scale (PSP-CDS) measure: Change From Baseline to Week 52 in Montreal Cognitive Assessment (MoCA) measure: Change From Baseline to Week 52 in PSP Quality of Life Scale (PSP-QoL) measure: Pharmacokinetic characterization of FNP-223 sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06355518 id: INu-RC briefTitle: Pre-operative Immuno-Nutrition in Radical Cystectomy acronym: INu-RC overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-09 date: 2026-09 date: 2024-04-09 date: 2024-04-09 name: Fondazione IRCCS Policlinico San Matteo di Pavia class: OTHER name: IRCCS Ospedale San Raffaele briefSummary: This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer. Patients receiving preoperative immunonutrition will be compared to controls receiving a standard high-calorie, high-protein oral nutritional supplement. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 260 type: ESTIMATED name: Immunonutrition name: Standard Oral Nutritional Supplement measure: 30-day complications measure: 30-day severe complications measure: 90-day severe complications measure: 30-day and 90-day infectious complications measure: 30-day and 90-day occurrence of other medical conditions measure: Time to recovery of bowel function measure: Time to postoperative mobilization measure: Muscular strength modifications measure: Weight modifications measure: Biochemical nutritional indexes modifications measure: Need of blood transfusions measure: Length of stay measure: Readmission rate measure: 30-day and 90-day mortality measure: Compliance measure: Tolerability (gastrointestinal symptoms related to nutritional supplement) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele city: Milan zip: 20132 country: Italy name: Bettiga Arianna role: CONTACT email: [email protected] name: Marco Moschini, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: Fondazione IRCCS Policlinico San Matteo city: Pavia zip: 27100 country: Italy name: Ferrari Alessandra, PharmD role: CONTACT phone: +390382503689 email: [email protected] name: Valentina Da Prat, MD role: PRINCIPAL_INVESTIGATOR lat: 45.19205 lon: 9.15917 hasResults: False
|
<|newrecord|> nctId: NCT06355505 id: PREPS-21-0098 briefTitle: Process of Emergence and Implementation of Advanced Practice Nursing in France acronym: PEIPA overallStatus: RECRUITING date: 2024-03-01 date: 2028-01-01 date: 2028-03-01 date: 2024-04-09 date: 2024-04-09 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: Longitudinal, observational research with a mixed quantitative (by questionnaires) and qualitative (by interviews and observations) approach, multidisciplinary, among Advanced Practice Nurses (APNs) already graduated and 3 consecutive classes of advanced practice students who will be followed annually during their implementation as APN until the last year of the study. The questionnaires will focus on APN scope of practice evolution, economical analysis and geographical distribution of APN. The ethnographical approach will assess APN settlements and relation with healthcare colleagues and patients. conditions: Nurse's Role studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 1600 type: ESTIMATED measure: Factors influencing the effective implementation of advanced practice nursing in France in primary care and health facilities measure: Mapping of APNs in France with socio-demographic data measure: Definition by the APN of its role and missions measure: Implementation and dissemination of the APN practice in the territory according to the context of practice (community care, hospital) measure: Identification of potential impact dimensions of Advanced Practice Nursing sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beaujon hospital status: RECRUITING city: Clichy zip: 92110 country: France name: Julie Devictor, PhD role: CONTACT phone: 06 64 71 26 75 email: [email protected] name: Anne Leclercq, PhD role: CONTACT phone: 0033 7 62 70 58 05 email: [email protected] lat: 48.90018 lon: 2.30952 hasResults: False
|
<|newrecord|> nctId: NCT06355492 id: 2090/10/30 briefTitle: Virtual Reality Distraction in Pediatric Patients. overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06 date: 2025-07 date: 2024-04-09 date: 2024-04-09 name: Tanta University class: OTHER briefSummary: The aim of this study is to evaluate the effect of virtual reality distraction on pain and anxiety during infiltration anesthesia in pediatric patients. conditions: Virtual Reality conditions: Distraction conditions: Infiltration Anesthesia conditions: Pediatric Patients studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 150 type: ESTIMATED name: Virtual reality goggles (VR ) name: regular screen measure: Assessment of pain during virtual reality distraction sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Rokia Abdelrhman Saad Elfaramawy city: Tanta state: El-Gharbia zip: 31527 country: Egypt name: Rokia A Elfaramawy, BDS role: CONTACT phone: 01069823221 email: [email protected] name: Fatma A Elhendawy, Professor role: SUB_INVESTIGATOR name: Nura I Abozena, Lecturer role: SUB_INVESTIGATOR lat: 30.78847 lon: 31.00192 hasResults: False
|
<|newrecord|> nctId: NCT06355479 id: HY1001-2022-P3 briefTitle: A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia overallStatus: COMPLETED date: 2023-04-10 date: 2023-11-22 date: 2023-12-12 date: 2024-04-09 date: 2024-04-09 name: Healthgen Biotechnology Corp. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia.
|
Researchers will compare OsrHSA to the positive comparator, plasma-derived HSA (pHSA) to see if OsrHSA presents as non-inferior to pHSA in the indication of hypoalbuminemia in hepatic cirrhosis patients.
|
Participants will be randomized in a 1:1 ratio to receive OsrHSA or HpHSA (20g IV qd) for up to 14 days, following an EOT visit. Follow-up visits will be taken on EOT+7d, EOT+14d, and EOT+30d, respectively. conditions: Hypoalbuminemia conditions: Hepatic Cirrhosis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 328 type: ACTUAL name: OsrHSA name: Plasbumin®-20 measure: To evaluate the efficacy of OsrHSA on elevating the serum albumin level. measure: To estimate the time to reach 35 g/L or more in serum albumin measure: To estimate the change from baseline in serum albumin measure: To estimate the change from baseline in colloid osmotic pressure measure: To estimate the change from baseline in body weight measure: To estimate the change from baseline in abdominal circumference, and ascites severity measure: To estimate the change from baseline in ascites severity sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital, Capital Medical University city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Beijing Youan Hospital, Capital Medical University city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Chongqing University Three Gorges Hospital city: Chongqing state: Chongqing country: China lat: 29.56278 lon: 106.55278 facility: The Second Affiliated Hospital of Chongqing Medical University city: Chongqing state: Chongqing country: China lat: 29.56278 lon: 106.55278 facility: Mengchao Hepatobiliary Hospital of Fujian Medical University city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 facility: The First Affiliated Hospital of Fujian Medical University city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 facility: Nanfang Hospital city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: The Third Affiliated Hospital, Sun Yat-Sen University city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Huizhou Central People's Hospital city: Huizhou state: Guangdong country: China lat: 23.11147 lon: 114.41523 facility: Affiliated Hospital of Guilin Medical University city: Guilin state: Guangxi country: China lat: 25.28194 lon: 110.28639 facility: Liuzhou Worker's Hospital city: Liuzhou state: Guangxi country: China facility: The First Affiliated Hospital of Guangxi Medical University city: Nanning state: Guangxi country: China lat: 22.81667 lon: 108.31667 facility: Affiliated Hospital Of Zunyi Medical University city: Zunyi state: Guizhou country: China lat: 27.68667 lon: 106.90722 facility: The Fourth Affiliated Hospital, Harbin Medical University city: Harbin state: Heilongjiang country: China lat: 45.75 lon: 126.65 facility: Luoyang Central Hospital city: Luoyang state: Henan country: China lat: 34.68361 lon: 112.45361 facility: The First Affiliated Hospital of Zhengzhou University city: Zhengzhou state: Henan country: China lat: 34.75778 lon: 113.64861 facility: The Sixth People's Hospital of Zhengzhou city: Zhengzhou state: Henan country: China lat: 34.75778 lon: 113.64861 facility: Jingzhou Central Hospital city: Jingzhou state: Hubei country: China lat: 30.35028 lon: 112.19028 facility: TaiHe Hospital city: Shiyan state: Hubei country: China lat: 32.6475 lon: 110.77806 facility: The Central Hospital of Wuhan city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Wuhan Jinyintan Hospital city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Yichang Central People's Hospital city: Yichang state: Hubei country: China lat: 30.71444 lon: 111.28472 facility: Yueyang Central Hospital city: Yueyang state: Hunan country: China lat: 29.37455 lon: 113.09481 facility: The Third People's Hospital of Zhenjiang city: Zhenjiang state: Jiangsu country: China lat: 32.21086 lon: 119.45508 facility: First Affiliated Hospital of Gannan Medical University city: Ganzhou state: Jiangxi country: China facility: The First Affiliated Hospital of Nanchang University city: Nanchang state: Jiangxi country: China lat: 28.68396 lon: 115.85306 facility: Pingxiang People's Hospital city: Pingxiang state: Jiangxi country: China lat: 27.61672 lon: 113.85353 facility: Yichun People's Hospital city: Yichun state: Jiangxi country: China lat: 47.72143 lon: 128.87529 facility: Hepatobiliary Hospital Of Jilin city: Chang chun state: Jilin country: China lat: 42.74694 lon: 126.24667 facility: The First Hospital of Jilin University city: Chang chun state: Jilin country: China lat: 42.74694 lon: 126.24667 facility: The Sixth People's Hospital of Shenyang city: Shenyang state: Liaoning country: China lat: 41.79222 lon: 123.43278 facility: The People's Hospital of Qinghai city: Xining state: Qinghai country: China lat: 36.62554 lon: 101.75739 facility: Shandong Public Health Clinical Center city: Jinan state: Shandong country: China lat: 36.66833 lon: 116.99722 facility: West China Hospital, Sichuan University city: Chengdu state: Sichuan country: China lat: 30.66667 lon: 104.06667 facility: The Second Affiliated Hospital of Kunming Medical University city: Kunming state: Yunnan country: China lat: 25.03889 lon: 102.71833 facility: Ruian People's Hospital city: Rui'an state: Zhejiang country: China facility: The First School of Medicine, School of Information and Engineering, The First Affiliated Hospital of Wenzhou Medical University city: Wenzhou state: Zhejiang country: China lat: 27.99942 lon: 120.66682 hasResults: False
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.